Does the media prefer TXG or PACB?

In the previous week, 10x Genomics had 6 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 8 mentions for 10x Genomics and 2 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 0.96 beat Pacific Biosciences of California's score of 0.27 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacific Biosciences of California 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate LMNX or PACB?

Pacific Biosciences of California has a consensus target price of $1.83, suggesting a potential upside of 11.45%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than Defiance Daily Target 2X Long LMND ETF. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Defiance Daily Target 2X Long LMND ETF 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pacific Biosciences of California 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80

Does the media refer more to LMNX or PACB?

In the previous week, Defiance Daily Target 2X Long LMND ETF and Defiance Daily Target 2X Long LMND ETF both had 2 articles in the media. Pacific Biosciences of California's average media sentiment score of 0.27 beat Defiance Daily Target 2X Long LMND ETF's score of 0.00 indicating that Pacific Biosciences of California is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Defiance Daily Target 2X Long LMND ETF 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pacific Biosciences of California 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pacific Biosciences of California (PACB) Competitors

$1.64 -0.04 (-2.08%)

As of 10:16 AM Eastern

Compare

PACB vs. TXG, HBIO, LMNX, TMO, and A

Should you buy Pacific Biosciences of California stock or one of its competitors? MarketBeat compares Pacific Biosciences of California with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pacific Biosciences of California include 10x Genomics (TXG), Harvard Bioscience (HBIO), Defiance Daily Target 2X Long LMND ETF (LMNX), Thermo Fisher Scientific (TMO), and Agilent Technologies (A).

How does Pacific Biosciences of California compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, 10x Genomics had 6 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 8 mentions for 10x Genomics and 2 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 0.96 beat Pacific Biosciences of California's score of 0.27 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10x Genomics currently has a consensus price target of $25.92, suggesting a potential downside of 33.28%. Pacific Biosciences of California has a consensus price target of $1.83, suggesting a potential upside of 11.45%. Given Pacific Biosciences of California's higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

10x Genomics has a net margin of -3.55% compared to Pacific Biosciences of California's net margin of -80.35%. 10x Genomics' return on equity of -2.86% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%

84.7% of 10x Genomics shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

10x Genomics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	7.67	-$43.54M	-$0.17	N/A
Pacific Biosciences of California	$160.01M	3.19	-$546.38M	-$0.43	N/A

Summary

10x Genomics beats Pacific Biosciences of California on 13 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Harvard Bioscience?

Pacific Biosciences of California (NASDAQ:PACB) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap life sciences tools & services companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Pacific Biosciences of California had 1 more articles in the media than Harvard Bioscience. MarketBeat recorded 2 mentions for Pacific Biosciences of California and 1 mentions for Harvard Bioscience. Pacific Biosciences of California's average media sentiment score of 0.27 beat Harvard Bioscience's score of 0.00 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pacific Biosciences of California has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Harvard Bioscience has a net margin of -11.44% compared to Pacific Biosciences of California's net margin of -80.35%. Harvard Bioscience's return on equity of -25.78% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%
Harvard Bioscience	-11.44%	-25.78%	-4.37%

Pacific Biosciences of California currently has a consensus target price of $1.83, indicating a potential upside of 11.45%. Harvard Bioscience has a consensus target price of $6.00, indicating a potential downside of 2.90%. Given Pacific Biosciences of California's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

80.9% of Harvard Bioscience shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by insiders. Comparatively, 20.3% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Harvard Bioscience has lower revenue, but higher earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	3.19	-$546.38M	-$0.43	N/A
Harvard Bioscience	$86.55M	0.32	-$56.70M	-$2.17	N/A

Summary

Harvard Bioscience beats Pacific Biosciences of California on 8 of the 15 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Defiance Daily Target 2X Long LMND ETF?

Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Pacific Biosciences of California has a consensus target price of $1.83, suggesting a potential upside of 11.45%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than Defiance Daily Target 2X Long LMND ETF.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Defiance Daily Target 2X Long LMND ETF	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Defiance Daily Target 2X Long LMND ETF and Defiance Daily Target 2X Long LMND ETF both had 2 articles in the media. Pacific Biosciences of California's average media sentiment score of 0.27 beat Defiance Daily Target 2X Long LMND ETF's score of 0.00 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Defiance Daily Target 2X Long LMND ETF	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Defiance Daily Target 2X Long LMND ETF has a net margin of 5.39% compared to Pacific Biosciences of California's net margin of -80.35%. Defiance Daily Target 2X Long LMND ETF's return on equity of 4.66% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%

Defiance Daily Target 2X Long LMND ETF has a beta of 7.91, suggesting that its stock price is 691% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Defiance Daily Target 2X Long LMND ETF, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Defiance Daily Target 2X Long LMND ETF	$437.66M	0.02	$15.17M	$0.51	46.06
Pacific Biosciences of California	$160.01M	3.19	-$546.38M	-$0.43	N/A

87.8% of Defiance Daily Target 2X Long LMND ETF shares are held by institutional investors. 6.6% of Defiance Daily Target 2X Long LMND ETF shares are held by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Defiance Daily Target 2X Long LMND ETF beats Pacific Biosciences of California on 10 of the 15 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Thermo Fisher Scientific?

Pacific Biosciences of California (NASDAQ:PACB) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Thermo Fisher Scientific has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	3.19	-$546.38M	-$0.43	N/A
Thermo Fisher Scientific	$44.56B	4.23	$6.70B	$18.19	27.91

Pacific Biosciences of California has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 3.7% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pacific Biosciences of California currently has a consensus price target of $1.83, indicating a potential upside of 11.45%. Thermo Fisher Scientific has a consensus price target of $605.09, indicating a potential upside of 19.19%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Thermo Fisher Scientific is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Thermo Fisher Scientific	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

In the previous week, Thermo Fisher Scientific had 32 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 34 mentions for Thermo Fisher Scientific and 2 mentions for Pacific Biosciences of California. Thermo Fisher Scientific's average media sentiment score of 1.50 beat Pacific Biosciences of California's score of 0.27 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Thermo Fisher Scientific	32 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Thermo Fisher Scientific has a net margin of 15.15% compared to Pacific Biosciences of California's net margin of -80.35%. Thermo Fisher Scientific's return on equity of 16.86% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%
Thermo Fisher Scientific	15.15%	16.86%	8.15%

Summary

Thermo Fisher Scientific beats Pacific Biosciences of California on 15 of the 17 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Agilent Technologies?

Pacific Biosciences of California (NASDAQ:PACB) and Agilent Technologies (NYSE:A) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Pacific Biosciences of California has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

Agilent Technologies has a net margin of 19.55% compared to Pacific Biosciences of California's net margin of -80.35%. Agilent Technologies' return on equity of 24.33% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%
Agilent Technologies	19.55%	24.33%	12.99%

Agilent Technologies has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	3.19	-$546.38M	-$0.43	N/A
Agilent Technologies	$6.95B	5.24	$1.30B	$4.98	25.87

In the previous week, Agilent Technologies had 3 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 5 mentions for Agilent Technologies and 2 mentions for Pacific Biosciences of California. Agilent Technologies' average media sentiment score of 1.21 beat Pacific Biosciences of California's score of 0.27 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agilent Technologies	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacific Biosciences of California presently has a consensus price target of $1.83, indicating a potential upside of 11.45%. Agilent Technologies has a consensus price target of $160.88, indicating a potential upside of 24.85%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Agilent Technologies is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Agilent Technologies	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

Summary

Agilent Technologies beats Pacific Biosciences of California on 14 of the 15 factors compared between the two stocks.

Get Pacific Biosciences of California News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PACB vs. The Competition

Export

Metric	Pacific Biosciences of California	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$514.66M	$7.48B	$6.87B	$12.56B
Dividend Yield	N/A	1.31%	2.66%	6.52%
P/E Ratio	-3.85	52.76	27.74	24.90
Price / Sales	3.19	84.24	528.47	93.72
Price / Cash	2.13	27.33	29.65	49.23
Price / Book	82.25	7.50	11.10	6.56
Net Income	-$546.38M	$159.19M	$3.57B	$336.14M
7 Day Performance	-4.91%	1.00%	2.22%	2.79%
1 Month Performance	13.45%	0.51%	7.13%	5.62%
1 Year Performance	4.11%	3.91%	33.77%	25.43%

Pacific Biosciences of California Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PACB Pacific Biosciences of California	0.8759 of 5 stars	$1.65 -2.1%	$1.83 +11.4%	+6.3%	$514.66M	$160.01M	N/A	730
TXG 10x Genomics	1.7859 of 5 stars	$37.15 +1.1%	$24.00 -35.4%	+199.8%	$4.67B	$642.82M	N/A	1,240
HBIO Harvard Bioscience	0.855 of 5 stars	$6.13 +1.5%	$6.00 -2.1%	+37.9%	$27.24M	$86.55M	N/A	490
LMNX Defiance Daily Target 2X Long LMND ETF	N/A	$15.18 +12.5%	N/A	N/A	$5.01M	$437.66M	29.77	1,325
TMO Thermo Fisher Scientific	4.8398 of 5 stars	$505.09 -1.5%	$605.09 +19.8%	+22.0%	$190.65B	$44.56B	27.77	125,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PACB) was last updated on 7/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, HBIO, LMNX, TMO, and A

How does Pacific Biosciences of California compare to 10x Genomics?

Summary

How does Pacific Biosciences of California compare to Harvard Bioscience?

Summary

How does Pacific Biosciences of California compare to Defiance Daily Target 2X Long LMND ETF?

Summary

How does Pacific Biosciences of California compare to Thermo Fisher Scientific?

Summary

How does Pacific Biosciences of California compare to Agilent Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, HBIO, LMNX, TMO, and A

How does Pacific Biosciences of California compare to 10x Genomics?

Does the media prefer TXG or PACB?

Do analysts rate TXG or PACB?

Is TXG or PACB more profitable?

Do institutionals & insiders hold more shares of TXG or PACB?

Which has more volatility & risk, TXG or PACB?

Which has better earnings & valuation, TXG or PACB?

Summary

How does Pacific Biosciences of California compare to Harvard Bioscience?

Does the media refer more to PACB or HBIO?

Which has more risk and volatility, PACB or HBIO?

Is PACB or HBIO more profitable?

Do analysts prefer PACB or HBIO?

Do institutionals & insiders hold more shares of PACB or HBIO?

Which has preferable earnings & valuation, PACB or HBIO?

Summary

How does Pacific Biosciences of California compare to Defiance Daily Target 2X Long LMND ETF?

Do analysts rate LMNX or PACB?

Does the media refer more to LMNX or PACB?

Is LMNX or PACB more profitable?

Which has more risk and volatility, LMNX or PACB?

Which has preferable earnings and valuation, LMNX or PACB?

Do insiders & institutionals have more ownership in LMNX or PACB?

Summary

How does Pacific Biosciences of California compare to Thermo Fisher Scientific?

Which has better valuation and earnings, PACB or TMO?

Which has more risk and volatility, PACB or TMO?

Do institutionals and insiders believe in PACB or TMO?

Do analysts rate PACB or TMO?

Does the media favor PACB or TMO?

Is PACB or TMO more profitable?

Summary

How does Pacific Biosciences of California compare to Agilent Technologies?

Which has more risk and volatility, PACB or A?

Is PACB or A more profitable?

Which has better earnings and valuation, PACB or A?

Does the media prefer PACB or A?

Do analysts recommend PACB or A?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools